Kyverna Therapeutics announced the appointment of Warner Biddle as the company’s CEO and a member of its Board of Directors. Biddle succeeds Peter Maag, Ph.D., who has resigned from his role as CEO and a member of the Board, effective immediately. In addition, Kyverna announced the appointment of Christi Shaw to its Board of Directors. Shaw succeeds Brian Kotzin, M.D., who has decided to step down from the Board of Directors. Biddle is a seasoned pharmaceutical executive, with over 30 years of global experience in senior commercial and franchise leadership roles across various products, disease areas and geographies. Most recently, he served as Senior Vice President, Global Head of Commercial at Kite Pharma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics treatment of stiff person syndrome gets orphan designation
- Kyverna Therapeutics price target lowered to $7 from $8 at H.C. Wainwright
- Kyverna Therapeutics reports Q2 EPS (67c), consensus (70c)
- Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
- Kyverna Therapeutics receives U.S. FDA RMAT designation for KYV-101